The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance. Yang G, Wang J, Tan L, Munshi M, et al. Blood 2021;138:1966-1979.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Yang G, Wang J, Tan L, Munshi M, et al. The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance. Blood 2021;138:1966-1979.
PMID: 34132782